ライブ
BioPharma DiveSummit pulls $500M share sale a day after announcing itEndpoints NewsDrugmakers are turning to logistics providers as trade disruptions linger, DHL exec saysBioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyEndpoints NewsSummit withdraws $500M offering, citing 'market conditions'Clinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer DetectionEndpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyEndpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cutsFierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekBioPharma DiveNovartis RNA drug acquired in $12B Avidity deal notches a trial winEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamPharmaVoiceCompetition is brewing between ADCs and bispecifics
BioWorld 2025年11月25日

Protara sees Chugai blue sky in LMs as phase II data strong

Protara sees Chugai blue sky in LMs as phase II data strong

原文
本文は利用できません。元の情報源をご確認ください。